Management of high-risk corneal transplantation
- 22 December 2016
- journal article
- review article
- Published by Elsevier BV in Survey of Ophthalmology
- Vol. 62 (6), 816-827
- https://doi.org/10.1016/j.survophthal.2016.12.010
Abstract
No abstract availableKeywords
Funding Information
- NIH/NEI (EY-12963)
This publication has 159 references indexed in Scilit:
- Corneal Neovascularization and the Utility of Topical VEGF Inhibition: Ranibizumab (Lucentis) Vs Bevacizumab (Avastin)The Ocular Surface, 2012
- Efficacy of Postoperative Immunosuppression After Keratoplasty in Herpetic KeratitisCornea, 2011
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2011
- High-risk corneal allografts and why they lose their immune privilegeCurrent Opinion in Allergy and Clinical Immunology, 2010
- High-frequency Topical Cyclosporine 0.05% in the Treatment of Severe Dry Eye Refractory to Twice-daily RegimenCornea, 2009
- Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytesNature Medicine, 2007
- Blockade of the 4‐1BB (CD137)/4‐1BBL and/or CD28/CD80/CD86 costimulatory pathways promotes corneal allograft survival in miceImmunology, 2007
- Tacrolimus immunosuppression in high-risk corneal graftsBritish Journal of Ophthalmology, 2006
- Tacrolimus (FK506) in the management of high-risk corneal and limbal graftsOphthalmology, 2001
- Reduced Graft Rejection with Good HLA-A and B Matching in High-Risk Corneal TransplantationNew England Journal of Medicine, 1986